EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics

Juan Carlos Rubilar, Tiago Fleming Outeiro iD, Andrés D Klein

Brain · 01.08.2024 · 147 (8) · 2610-2620

DOI: 10.1093/brain/awae070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 04.03.2024. Verfasst von Juan Carlos Rubilar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7780272, Chile. Hauptthemen laut MEDLINE: Glucosylceramidase, Lysosomes, Mitochondria, Parkinson Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 133 Literaturangaben. Gefördert von: ANID-CHILE, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease is a neurodegenerative disorder primarily known for typical motor features that arise due to the loss of dopaminergic neurons in the substantia nigra. However, the precise molecular aetiology of the disease is still unclear. Several cellular pathways have been linked to Parkinson’s disease, including the autophagy-lysosome pathway, α-synuclein aggregation and mitochondrial function. Interestingly, the mechanistic link between GBA1, the gene that encodes for lysosomal β-glucocerebrosidase (GCase), and Parkinson’s disease lies in the interplay between GCase functions in the lysosome and mitochondria. GCase mutations alter mitochondria-lysosome contact sites. In the lysosome, reduced GCase activity leads to glycosphingolipid build-up, disrupting lysosomal function and autophagy, thereby triggering α-synuclein accumulation. Additionally, α-synuclein aggregates reduce GCase activity, creating a self-perpetuating cycle of lysosomal dysfunction and α-synuclein accumulation. GCase can also be imported into the mitochondria, where it promotes the integrity and function of mitochondrial complex I. Thus, GCase mutations that impair its normal function increase oxidative stress in mitochondria, the compartment where dopamine is oxidized. In turn, the accumulation of oxidized dopamine adducts further impairs GCase activity, creating a second cycle of GCase dysfunction. The oxidative state triggered by GCase dysfunction can also induce mitochondrial DNA damage which, in turn, can cause dopaminergic cell death. In this review, we highlight the pivotal role of GCase in Parkinson’s disease pathogenesis and discuss promising examples of GCase-based therapeutics, such as gene and enzyme replacement therapies, small molecule chaperones and substrate reduction therapies, among others, as potential therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosylceramidaseLysosomesMitochondriaParkinson DiseaseHumansAnimalsalpha-SynucleinAutophagyMutation

Stichwörter der Autor:innen

Gaucher’s diseaseParkinson’s diseaselysosomemitochondrianeurodegenerationtherapeutics

Substanzen

Glucosylceramidasealpha-Synuclein

Autor:innen und Institutionen

  • Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7780272, Chile.
  • Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073, Göttingen, Germany.
  • Max Planck Institute for Natural Sciences, 37073, Göttingen, Germany.
  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.
  • Scientific Employee with an Honorary Contract at Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), 37075, Göttingen, Germany.

ORCID-Profile: Tiago Fleming Outeiro

Förderung

  • ANID-CHILE
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Rubilar, J. C., Outeiro, T. F., & Klein, A. D. (2024). The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics. Brain, 147(8), 2610-2620. https://doi.org/10.1093/brain/awae070

Vancouver

Rubilar JC, Outeiro TF, Klein AD. The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics. Brain. 2024;147(8):2610-2620. doi:10.1093/brain/awae070

BibTeX
@article{Rubilar2024,
  author = {Rubilar, Juan Carlos and Outeiro, Tiago Fleming and Klein, Andrés D},
  title = {The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {8},
  pages = {2610--2620},
  doi = {10.1093/brain/awae070}
}
Kostenlos starten →